Is Alvotech about to reshape Europe’s anti-TNF market with its Simponi biosimilar?

Alvotech (NASDAQ: ALVO) and its partner STADA Arzneimittel AG have launched Uzpruvo, a biosimilar to Johnson & Johnson’s Simponi (golimumab), across several European countries following centralized marketing authorization from the European Commission. The launch marks the first and only approved biosimilar to Simponi available in the European Economic Area (EEA), entering the rheumatoid arthritis and inflammatory disease space with broad treatment labels for adult and pediatric patients.

How does Uzpruvo’s launch alter the dynamics of Europe’s anti-TNF biosimilar market?

The arrival of Uzpruvo into Europe’s crowded yet commercially valuable anti-TNF-alpha therapy class reflects both strategic timing and biosimilar market maturation. Golimumab had long stood apart from earlier anti-TNF agents such as infliximab and adalimumab, which faced biosimilar erosion as early as 2013 in Europe. Simponi, by contrast, retained exclusivity for longer due to its later entry, subcutaneous administration advantage, and once-monthly dosing convenience, making it a preferred option for both patients and providers in long-term maintenance therapy.

With the launch of Uzpruvo, STADA and Alvotech are positioned to challenge Johnson & Johnson’s Simponi franchise at a point when payers are eager to unlock cost savings. While Simponi generated $1.6 billion globally in 2023 revenue, with Europe representing a significant share, its biosimilar-free status made it an anomaly among anti-TNFs. That gap has now closed.

The marketing authorization granted by the European Commission is based on a Phase 3 confirmatory study in rheumatoid arthritis that met its primary endpoint of therapeutic equivalence, enabling Uzpruvo to share the full indication set of Simponi. This includes moderate to severe rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and ulcerative colitis—some of the most cost-intensive chronic autoimmune conditions in Europe’s healthcare systems.

Why are STADA and Alvotech jointly pursuing the Simponi biosimilar opportunity?

STADA’s commercialization rights across Europe, coupled with Alvotech’s manufacturing and development platform, represent a division of labor increasingly common in biosimilar alliances. STADA, which already markets biosimilars such as Terrosa (teriparatide) and Movymia, brings local market access and established payer relationships in Europe. Alvotech, meanwhile, leverages its vertically integrated biologics platform to compete on cost and quality with incumbents.

Alvotech is also attempting to scale a global biosimilar portfolio by deploying this partnership model in multiple markets. The company has similar co-commercialization agreements in the United States with Teva Pharmaceuticals, in Japan with Fuji Pharma, and in Canada and Australia with JAMP and Arrotex, respectively. Uzpruvo’s European launch serves as both a revenue catalyst and a proof point for Alvotech’s broader manufacturing and regulatory infrastructure.

For STADA, adding a differentiated biosimilar such as golimumab helps diversify its immunology pipeline, especially as European health systems increasingly favor biosimilar substitution in tender processes and hospital formularies. The fact that Uzpruvo is the first and currently only golimumab biosimilar in the EEA gives it a rare first-mover edge—a strategic advantage often elusive in other biosimilar categories dominated by multiple players.

What commercial and policy factors will shape Uzpruvo’s adoption in Europe?

The commercial success of Uzpruvo will largely depend on country-level pricing, tender penetration, and payer willingness to enforce or encourage biosimilar switches. While countries like Norway, the Netherlands, and the United Kingdom have been aggressive in biosimilar adoption through centralized procurement and physician incentives, others such as Germany and Italy exhibit more fragmented uptake due to regional payer structures.

Another factor is therapeutic inertia. Physicians accustomed to prescribing Simponi may be more reluctant to switch patients on stable regimens unless strong pricing or reimbursement incentives exist. However, the full label granted to Uzpruvo lowers the clinical hesitation often associated with limited biosimilar indications and could support confidence in switching practices.

From a policy standpoint, the European Commission and national governments continue to view biosimilars as a critical cost-containment lever. The introduction of a golimumab biosimilar helps strengthen biosimilar penetration into late-stage biologic therapies, where savings potential remains underexploited. The expected discount range—typically 20–40% off reference product prices—could translate into hundreds of millions of euros in annual payer savings if broadly adopted.

How does Uzpruvo position Alvotech in the global biosimilar hierarchy?

Alvotech’s European launch of Uzpruvo advances its ambition to be a top-tier global biosimilar pure-play, distinct from diversified players like Sandoz or Biocon Biologics. The company now has multiple late-stage biosimilars across autoimmune, oncology, and ophthalmology, including AVT04 (ustekinumab), AVT06 (aflibercept), and AVT03 (denosumab). Uzpruvo is the second product Alvotech has launched in Europe in collaboration with STADA, following the 2023 debut of Hukyndra (adalimumab).

Alvotech continues to face manufacturing scale-up and regulatory synchronization challenges, especially in the United States, where the Food and Drug Administration has delayed some of its biosimilars due to inspection findings. However, the European launch underscores Alvotech’s ability to secure centralized approvals and rapidly commercialize assets with regional partners.

Investor sentiment toward Alvotech has fluctuated due to delays in U.S. approvals and capital constraints, but the successful rollout of Uzpruvo in Europe may help rebuild credibility and drive near-term revenue growth. Alvotech has guided toward positive EBITDA in 2025, contingent on multiple biosimilar launches and ramp-ups.

What are the implications for Johnson & Johnson’s Simponi franchise in Europe?

For Johnson & Johnson, the launch of Uzpruvo may accelerate erosion of Simponi’s European revenues, which have remained relatively resilient compared to older anti-TNF assets. The strategic significance of Simponi has also diminished within Johnson & Johnson’s immunology portfolio, which now centers around newer agents like Tremfya (guselkumab) and Stelara (ustekinumab), both of which face biosimilar competition in the near term.

Johnson & Johnson is unlikely to aggressively defend Simponi’s pricing in markets where tendering dominates, particularly if volume retention proves difficult. The company may instead focus on lifecycle management strategies in the U.S., where Simponi retains stronger exclusivity.

What are the key takeaways from the launch of Uzpruvo in Europe?

• Alvotech and STADA have launched Uzpruvo, the first and only biosimilar to Simponi, in the European Economic Area.

• The launch targets a €1B+ market for golimumab and addresses key autoimmune indications, including rheumatoid arthritis and ulcerative colitis.

• Uzpruvo’s first-mover status gives it a strategic advantage in a typically competitive biosimilar category.

• STADA brings commercial infrastructure and payer access across Europe, while Alvotech leverages its global manufacturing platform.

• Country-level adoption will depend on tender structures, clinical switching behavior, and policy incentives.

• The launch strengthens Alvotech’s position as a biosimilar pure-play amid delayed U.S. approvals.

• Johnson & Johnson may deprioritize Simponi in Europe and focus on newer immunology assets under patent.

• European payers could see significant cost savings if Uzpruvo adoption reaches levels seen with earlier anti-TNF biosimilars.